Abstract 1658: CFT1946, a Potent, Selective BRAF V600X Mutant-Specific Degrader Demonstrates Superior Activity As a Single Agent to Clinically Approved BRAF Inhibitors and Standard of Care Combinations in Preclinical Models of BRAF V600X Melanoma, CRC, NSCLC, and Brain Metastasis